BioAge Labs, Inc. (BIOA)Healthcare | Drug Manufacturers - Specialty & Generic | EmeryVille, United States | NasdaqGS
6.34 USD
+0.13
(2.093%)
⇧
(Oct. 9, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8:23 a.m. EDT
The investment case for BioAge Labs is currently broken by a perfect storm of deteriorating fundamentals and overwhelming bearish sentiment. The company is hemorrhaging cash, with operating and free cash flows both deeply negative, while posting a massive 74% drop in share price over the last year. Despite a fortress-like balance sheet with negligible debt relative to its cash pile, the market has priced in a failure to execute, evidenced by the crushing decline in valuation multiples. The options market confirms this pessimism, with traders aggressively buying puts to hedge against further drops rather than betting on a rebound. While the wide gap between the current price and analyst targets suggests potential for a turnaround if clinical trials succeed, the immediate reality is a distressed asset with no income generation and a trajectory pointing lower. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.758016 |
| AutoETS | 0.758020 |
| AutoTheta | 0.760055 |
| MSTL | 0.769321 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 20% |
| H-stat | 2.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 4.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.756 |
| Revenue per Share | 0.26 |
| Market Cap | 290,986,400 |
| Forward P/E | -2.63 |
| Beta | 1.08 |
| Website | https://bioagelabs.com |
As of Oct. 10, 2026, 8:23 a.m. EDT: Speculators are heavily positioned for downside protection with significant open interest in out-of-the-money puts (strikes 2.5, 5.0, 7.5) across multiple expirations, indicating a fear of further decline. Conversely, call activity is sparse and concentrated at very distant strikes (35-40), suggesting minimal speculative belief in a near-term recovery despite the wide analyst target range.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.15272725 |
| Address1 | 5,885 Hollis Street |
| Address2 | Suite 370 |
| All Time High | 26.62 |
| All Time Low | 2.88 |
| Ask | 7.96 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 984,750 |
| Average Daily Volume3 Month | 918,171 |
| Average Volume | 918,171 |
| Average Volume10Days | 984,750 |
| Beta | 1.081 |
| Bid | 4.63 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 8.19 |
| City | EmeryVille |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.34 |
| Current Ratio | 17.189 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,789,430,400 |
| Day High | 6.47 |
| Day Low | 6.145 |
| Debt To Equity | 0.756 |
| Display Name | BioAge Labs |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -106,020,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.27 |
| Enterprise To Revenue | -2.762 |
| Enterprise Value | -28,595,350 |
| Eps Current Year | -2.37377 |
| Eps Forward | -2.41435 |
| Eps Trailing Twelve Months | -2.39 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.9511 |
| Fifty Day Average Change | -2.6111002 |
| Fifty Day Average Change Percent | -0.2917072 |
| Fifty Two Week Change Percent | 15.272724 |
| Fifty Two Week High | 25.955 |
| Fifty Two Week High Change | -19.615 |
| Fifty Two Week High Change Percent | -0.75573105 |
| Fifty Two Week Low | 5.04 |
| Fifty Two Week Low Change | 1.3000002 |
| Fifty Two Week Low Change Percent | 0.25793654 |
| Fifty Two Week Range | 5.04 - 25.955 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,727,357,400,000 |
| Float Shares | 39,189,535 |
| Forward Eps | -2.41435 |
| Forward P E | -2.6259656 |
| Free Cashflow | -58,067,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 60 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 6.34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -77,433,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.023610001 |
| Held Percent Institutions | 0.90615 |
| Implied Shares Outstanding | 45,896,909 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California. |
| Long Name | BioAge Labs, Inc. |
| Market | us_market |
| Market Cap | 290,986,400 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_529779470 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -94,464,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 360,749,704 |
| Number Of Analyst Opinions | 8 |
| Open | 6.21 |
| Operating Cashflow | -87,601,000 |
| Operating Margins | -11.96777 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 510 806 1445 |
| Pre Market Change | 0.0 |
| Pre Market Change Percent | 0.0 |
| Pre Market Price | 6.34 |
| Pre Market Time | 1,791,792,003 |
| Previous Close | 6.21 |
| Price Eps Current Year | -2.670857 |
| Price Hint | 2 |
| Price To Book | 0.77411485 |
| Price To Sales Trailing12 Months | 28.101053 |
| Profit Margins | 0.0 |
| Quick Ratio | 16.749 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.13000011 |
| Regular Market Change Percent | 2.0933995 |
| Regular Market Day High | 6.47 |
| Regular Market Day Low | 6.145 |
| Regular Market Day Range | 6.145 - 6.47 |
| Regular Market Open | 6.21 |
| Regular Market Previous Close | 6.21 |
| Regular Market Price | 6.34 |
| Regular Market Time | 1,791,576,001 |
| Regular Market Volume | 667,340 |
| Return On Assets | -0.18474 |
| Return On Equity | -0.28211 |
| Revenue Growth | 0.016 |
| Revenue Per Share | 0.26 |
| Sand P52 Week Change | 0.17383456 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 45,896,909 |
| Shares Percent Shares Out | 0.067 |
| Shares Short | 3,073,976 |
| Shares Short Previous Month Date | 1,786,665,600 |
| Shares Short Prior Month | 2,217,521 |
| Short Name | BioAge Labs, Inc. |
| Short Percent Of Float | 0.0753 |
| Short Ratio | 5.6 |
| Source Interval | 15 |
| State | CA |
| Symbol | BIOA |
| Target High Price | 73.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 35.625 |
| Target Median Price | 30.0 |
| Total Cash | 318,744,992 |
| Total Cash Per Share | 6.945 |
| Total Debt | 2,835,000 |
| Total Revenue | 10,355,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 16.5415 |
| Two Hundred Day Average Change | -10.2015 |
| Two Hundred Day Average Change Percent | -0.6167216 |
| Type Disp | Equity |
| Volume | 667,340 |
| Website | https://bioagelabs.com |
| Zip | 94,608 |